It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
AI Meets Expertise: A hybrid Workflow For Modern Target ID | QIAGEN & Sygnature
In drug discovery, generating targets is no longer the challenge.
The real question is how to identify the few worth investing months of research and significant resources to pursue.
Hear expert perspectives on how AI, pathway analysis and scientific expertise are shaping modern target identification.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Cautionary Tales: Identifying Hidden Challenges in Insect Cell Protein Production
The Challenge
Baculovirus expression systems are widely used to produce secreted, intracellular, and membrane proteins. These expression systems can be particularly valuable for difficult eukaryotic targets. In many projects, expression levels and purification yields are the primary measures of success.
However, successful expression does not always guarantee that the final protein is suitable for its intended downstream application.
At Sygnature Discovery, protein characterization forms an important part of our protein production workflows, helping to identify issues that are not always apparent from expression levels or standard purification data alone.
Two projects highlighted how additional analytical investigation revealed challenges that would otherwise have been missed.
Project 1: When Expression Success Doesn’t Translate into Purification Success
A secreted protein containing a C-terminal 3C protease-10His-TwinStrep tag was expressed in Hi5 insect cells.
Initial small-scale feasibility studies suggested that expression levels were acceptable, and intact mass analysis confirmed the presence of protein with the expected molecular weight. However, when the process was scaled to 3 L, purification results became highly variable, and the target protein could not be consistently recovered using Strep-Tactin affinity chromatography.
Figure 1. Comparable PAGE showing in process samples from small scale feasibility (left) and scale up (right)
Further investigation revealed an additional protein species approximately 4.8 kDa smaller than expected. Mass analysis suggested that proteolytic cleavage had occurred within the C-terminal tag region.
To better understand the process, an expression time-course study was performed. Proteins harvested after 48 hours could still be purified successfully, whereas proteins harvested after 72 and 96 hours could not.
These results demonstrated that proteolytic degradation was occurring during expression and identified harvest timing as an important factor influencing product quality.
Project 2: When Protein Purifies Correctly but Doesn’t Perform as Expected
In a second project, two versions of a target protein were produced:
A C-terminal 10His-Avi tagged construct intended for biotinylation and SPR studies.
A C-terminal 6His construct intended for structural biology studies.
Both proteins expressed well in Sf9 cells and followed comparable purification profiles using nickel affinity chromatography, ion exchange chromatography, and size exclusion chromatography.
At first glance, both proteins appeared highly similar. SDS-PAGE analysis and thermal stability measurements produced results consistent with expectations.
However, the Avi-tagged construct performed poorly during immobilization onto streptavidin surfaces.
Subsequent mass spectrometry analysis showed that the difference in molecular mass between the two constructs was significantly smaller than expected, strongly suggesting that the Avi tag had been removed.
Although expression and purification had been successful, the protein was not suitable for its intended downstream application because the functional tag had been lost during expression.
Understanding the Root Cause
These projects highlighted two common factors:
First, extended C-terminal tags are often relatively unstructured and may therefore be more susceptible to proteolytic degradation.
Second, baculovirus-infected insect cell cultures can contain significant protease activity, particularly at later harvest time points. As viral infection progresses and cell viability decreases, protease release can increase substantially.
This combination can create challenges when expressing secreted proteins containing long affinity or functional tags.
The Value of Protein Characterization
In both projects, protein expression and initial purification appeared successful. Without further characterization, the underlying issues may have remained undetected until much later in the workflow.
These examples demonstrate why protein production involves more than generating a detectable protein band or achieving a target yield. Understanding protein integrity, confirming the presence of functional tags, and assessing suitability for downstream applications is equally important.
By combining protein expression, purification, and detailed characterization, scientists can identify issues early and adapt construct design, harvest strategies, or expression systems before they become significant project bottlenecks.
Outcome
Through detailed analytical investigation, the source of the observed performance issues was identified in both projects. The findings provided guidance for future construct design and expression strategies, particularly for secreted proteins produced in baculovirus-infected insect cells.
These studies also reinforced the importance of evaluating protein quality alongside expression yield when producing proteins for structural biology, biophysical characterization, and assay development.